Neil Patil, M.P.P.

Senior Fellow
Policy Director

Neil Patil is a Senior Fellow and the Policy Director at MPI. He conducts policy analysis and provides technical assistance to policymakers on Medicare Advantage issues.

Prior to joining MPI, Neil was a Senior Analyst at the Centers for Medicare & Medicaid Services Office of Legislation, where he provided technical assistance to Congress on issues related to Medicare Advantage and the Medicare Drug Price Negotiation Program. In this role, he served as the lead analyst on Medicare Advantage issues. He was also instrumental in supporting the passage and early implementation of Medicare drug pricing policies included in the Inflation Reduction Act. Neil has also served as the Legislative Assistant/Clerk in the U.S. House of Representatives, Committee on Ways and Means and as a Policy Associate for the U.S. Senate Committee on Finance. In these roles, his work has focused on issues related to Medicare reform, drug pricing, nursing home oversight, health equity, as well as other Medicare issues.

Neil holds a Master of Public Policy from Georgetown University’s McCourt School of Public Policy and a Bachelor of Arts in Economics from Xavier University.

MPI Publications

• The Push for Medicare Advantage Transparency: How Recent Legislation in the House Targets Existing Data Gaps 
• ​​CMS’s WISeR Model Faces Potential Repeal Following GAO Determination
• Medicare Advantage Insurers and Brokers Fail to Toss Whistleblower Lawsuit
• Contract Year 2027 Medicare Advantage and Part D Proposed Rule
• From “Flat” to Favorable: How Medicare Advantage Payments Increased in the Calendar Year (CY) 2027 Rate Announcement
• How CMS Policies to Reverse Protections for Medicare Beneficiaries Reflect a Broader Deregulatory Push 
• The Game(ing) isn’t Over: Upcoding After v28
• CMS Takes Aim at Upcoding: Ending “Unlinked” Chart Reviews in Medicare Advantage
• Apples to Oranges: Including the MA Risk Score Trend in CMS’s Estimates of MA Payments
• A Comparison of 2025 Medicare Advantage Legislation
• A Comparison of the Improving Seniors’ Timely Access to Care Act of 2025 and CMS Rulemaking
• Fact Sheet: A Policymaker’s Guide to Medicare Advantage Payment
• Drug Pricing in the Era of Trump 2.0
• The Impact of Health Risk Assessments and Chart Reviews on Medicare Advantage Payment
• New CMS WISeR Model Revives Concerns of Prior Authorization and Artificial Intelligence
• Medicare Advantage Whistleblower Lawsuit Alleges Insurer and Broker Misconduct
• The Trump Administration’s First Regulatory Action on Medicare Advantage Omits Some Prior Authorization Guardrails